Insider buying last 90 days
No open-market insider purchases were filed for BBIO in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
BridgeBio reported stronger third-quarter 2026 results, with revenue of $353.17 million and a net loss of $56.71 million, an improvement from the prior year. The quarter's narrative centers on Attruby, which the company said is annualizing to over $1 billion in U.S. revenue, alongside anticipation of upcoming launches including BBP-418, with an FDA decision nearing on November 27, infigratinib, and encaleret. The company also announced equity grants to new employees and plans to present new acoramidis data at the American Heart Association Scientific Sessions 2026, while management is set to appear at several investor conferences in November and December.
BBIO closed at $77.93, up 4.9%, sitting above both its 50-day average of $69.79 and 200-day average of $72.68. The GekkoIndex reads 47, placing the stock in the Neutral zone. Shares trade 7.9% below Gekko Fair Value of $84.60. One-month return stands at 19.3%, though the three-month return is negative at -6.9%, reflecting mixed short-term performance against a stronger six-month return of 20.5%.
The next earnings date falls on 23 February 2027, outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in their respective windows, though one billionaire holder is recorded. Seasonality data shows the next 20 trading days have averaged a 2.8% return over 5 years, with gains in 4 of those years. The pending BBP-418 FDA decision on 27 November and continued Attruby commercial progress remain relevant through this period, alongside consensus analyst coverage showing 17 buy ratings among 18 firms.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
BridgeBio Pharma scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
Averages disagree
Close $78.30 sits between the 50-day ($69.98) and 200-day ($72.69) averages, or the averages disagree.
See the chart50.2, Neutral
Reading 50.2 is in the Neutral zone.
See the GekkoIndex7.6% below
Price is 7.6% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 100 days
Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.
See earnings+1.9% on average
From this point in the calendar, the next 20 trading days averaged +1.9% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
BridgeBio Pharma closed at $78.30 on Nov 13, 2026, +18.2% over the past year, inside a 52-week range of $62.50 to $93.42.
Use the left and right arrow keys to read daily values.
Put BBIO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
BridgeBio Pharma works on finding and developing treatments for genetic conditions, following candidates from early research through late-stage clinical testing. Its pipeline includes a small molecule meant to stabilize transthyretin for a heart condition tied to transthyretin amyloidosis, a molecule targeting a childhood bone-growth disorder, a gene transfer candidate for a hormonal condition affecting the adrenal glands, a compound aimed at a rare form of low blood calcium, and a program addressing recurring kidney stones and related hyperoxaluria. Some of these programs have reached mid to late-stage clinical trials, while others remain in earlier testing.
The company also pursues work in rare Mendelian disorders, cancer-related diseases, and gene therapy more broadly, running roughly thirty development programs at once. It carries out some of this work through licensing and collaboration arrangements with outside research institutions, including a major university, a state university system, and a biomedical research organization, which support parts of its scientific pipeline.
BridgeBio Pharma was established in 2015 and is headquartered in Palo Alto, California. Its shares are listed on the NASDAQ under the ticker BBIO.
BridgeBio Pharma’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.2, in the Neutral zone, up 1.9 points over five sessions.
Up 1.9 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 35 | +1.4% | +2.1% | ||
| Accumulation | 194 | +1.3% | +3.3% | ||
| Neutral (current zone) | 434 | +0.5% | +2.6% | ||
| Distribution | 37 | −0.2% | +0.4% | ||
| Selling | 2 | Too few readings yet | |||
Average BBIO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
BridgeBio Pharma trades 7.6% below Gekko Fair Value of $84.73, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what BridgeBio Pharma shares are worth, recalculated every trading day.
$84.73
Gekko Fair Value, Nov 14, 2026
7.6% Undervalued
At the end of Aug 2026 the price was 22.2% below the estimate.
No open-market insider purchases were filed for BridgeBio Pharma, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for BBIO in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in BBIO were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
BridgeBio Pharma has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds BBIO.
BridgeBio Pharma reports on Feb 23, 2027, after the close (100 days away), and beat the EPS estimate in 1 of its last 8 reports.
Feb 23, 2027
Expected after the close, 100 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | −$0.42 est −$0.54 | $353.2M est $293.5M | +5.8% |
| Aug 10, 2026 | −$0.78 est −$0.58 | $243.7M est $220.9M | −0.9% |
| May 7, 2026 | −$0.84 est −$0.62 | $194.5M est $178.1M | −1.0% |
| Feb 24, 2026 | −$0.94 est −$0.72 | $154.2M est $146.8M | −2.0% |
| Oct 29, 2025 | −$0.95 est −$0.88 | $120.7M est $148.2M | −1.8% |
| Aug 5, 2025 | −$0.95 est −$0.83 | $110.6M est $108.1M | −6.2% |
| Apr 29, 2025 | −$0.99 est −$0.89 | $116.6M est $68.41M | +6.9% |
| Feb 20, 2025 | −$1.37 est −$1.09 | $5.88M est $4.04M | +1.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for BridgeBio Pharma is $106.85, +36.5% from the last close, from 17 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 17 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Morgan Stanley | $91 | +16.2% |
| Nov 2 | Barclays | $156 | +99.2% |
| Nov 2 | Canaccord Genuity | $108 | +37.9% |
| Oct 30 | Citi | $91 | +16.2% |
| Oct 30 | UBS | $92 | +17.5% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, BridgeBio Pharma averaged +1.9% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −8.4% | 1 of 5 |
| Next 10 trading days | −3.8% | 2 of 5 |
| Next 15 trading days | −0.1% | 3 of 5 |
| Next 20 trading days | +1.9% | 3 of 5 |
| Next 30 trading days | −7.9% | 3 of 5 |
For scale, BBIO’s typical 20-trading-day move in either direction is about 10.4%.
BridgeBio Pharma’s market cap is $15.25B and revenue of $945.5M over the last twelve months.
Coverage of BridgeBio Pharma this week reads neutral: 3 positive, 4 neutral and 1 negative headlines.
BridgeBio Pharma’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
BridgeBio Pharma’s market cap is $15.25B at the Nov 13, 2026 close of $78.30, with 194.8M shares outstanding.
The consensus analyst 12-month price target for BridgeBio Pharma is $106.85, +36.5% from the last close. Of the 17 firms that rated the stock in the last 90 days, 16 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate BridgeBio Pharma is undervalued: the Nov 13, 2026 close of $78.30 is 7.6% below Gekko Fair Value of $84.73. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
BridgeBio Pharma is expected to report on Feb 23, 2027, after the market closes (100 days away). Analysts expect earnings of −$0.59 per share on revenue of $310.8M. BridgeBio Pharma beat the earnings estimate in 1 of its last 8 reports, moving 3.3% on average across the report.
BridgeBio Pharma’s 52-week high is $93.42 and its 52-week low is $62.50; it closed at $78.30 on Nov 13, 2026, +18.2% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (fair value, earnings risk and seasonality), 2 as mixed (trend and gekkoindex). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.